IMPORTANCE Fluoroquinolones are among the most commonly prescribed antibiotics. Recent clinical studies indicated an association between fluoroquinolone use and increased risk of aortic aneurysm and dissection (AAD). This alarming association has raised concern, especially in patients with AAD with risk of rupture and in individuals at risk for developing AAD.
A ortic aneurysm and dissection (AAD) are common disorders that carry a significant risk of mortality and mobidity. 1 Avoiding factors that promote aortic damage, disease progression, and devastating rupture is critical in treating these patients. Fluoroquinolones are among the most commonly prescribed antibiotics worldwide [2] [3] [4] and are used to treat a variety of bacterial infections, [2] [3] [4] including infected aortic aneurysms. [5] [6] [7] Since they were first introduced in the 1980s, fluoroquinolones became popular because of their broad antimicrobial spectrum and favorable pharmacokinetic and pharmacodynamic characteristics, such as excellent oral bioavailability, extensive tissue penetration, and moderate to long elimination half-lives. 8 However, results of surveillance and clinical studies have indicated that fluoroquinolones are associated with several adverse effects, 9 including tendinitis and tendon rupture. [10] [11] [12] Because fluoroquinolones are associated with an increased risk of tendon rupture, the US Food and Drug Administration issued a black box warning in 2008 regarding the risk of tendon complications associated with fluoroquinolone use. 13 Recently, the results of 2 observational clinical studies have suggested that fluoroquinolone use may be associated with an increased risk of AAD. 14, 15 Although the causal effects remain to be determined, this alarming association has raised concern, especially in patients with AAD with risk of rupture and in individuals with risk of developing AAD. Importantly, because of the limitations of the currently available observational reports, the US Food and Drug Administration released a statement in May 2017 clarifying that "published studies do not currently support reports that these medicines may result in aortic aneurysm and aortic dissection." 16 Therefore,
given that rigorous prospective studies in patients are improbable and would be unethical, there is an acute need to study the risks of fluoroquinolones in experimental models.
To determine whether fluoroquinolone use can indeed cause AAD or increase the risk of AAD formation and progression, we examined the effect of ciprofloxacin-the most commonly used fluoroquinolone-on AAD development in a mouse model of moderate, sporadic AAD induced by challenging mice with a highfat diet and angiotensin II infusion. We found that although ciprofloxacin treatment alone did not induce spontaneous AAD in unchallenged mice, it significantly increased the incidence of aortic dissection and rupture in the thoracic and abdominal aortic regions of challenged mice and showed similar effects in male and female mice. Our findings support that ciprofloxacin increases susceptibility to AAD formation and aortic rupture.
Methods
Detailed methods and methods for supplement data are described in the eMethods in the Supplement. The study began in October 2016 and ended in September 2017. Analyses began in September 2017.
Animal Studies
We evaluated the effects of ciprofloxacin on AAD development in a mouse model of moderate, sporadic AAD. Mice were randomly assigned to 1 of 4 treatment groups. Four-week-old wild-type (C57BL/6J) male and female mice were challenged with a combination of a high-fat diet for 8 weeks and subcutaneous angiotensin II infusion during the last 4 weeks. Unchallenged control mice were fed a normal chow diet and were infused with saline. Both groups also received either ciprofloxacin or vehicle through daily gavage during the infusion period. At the end of the study, mice were killed, and aortas were processed for AAD evaluation and tissue analysis. All animal experiments were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine in accordance with the guidelines of the National Institutes of Health.
Evaluation of Aortic Aneurysm, Dissection, and Rupture and AAD Severity
For each extracted aorta, we evaluated the diameter of the ascending, arch, descending, suprarenal, and infrarenal aortic segments. Detailed methods for measuring aortic diameters; defining aortic dilatation, aneurysm, and dissection; and classifying AAD severity are described in the eMethods in the Supplement. Aortic rupture and premature death were documented.
Evaluation of Aortic Tissue
Aortic sections were stained with Verhoeff-van Gieson elastin staining, and elastic fiber fragmentation was scored. For immunofluorescence staining and quantification, aortic sections and treated cells were processed and analyzed as previously described. 17 Antibodies are listed in the eTable in the Supplement. For the analysis of matrix metalloproteinase (MMP) activity, we performed in situ zymography with frozen aortic sections. Lysyl oxidase (LOX) activity was measured by using a Lysyl Oxidase Activity Assay Kit (fluorometric) (Abcam, ab112139). Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) staining was performed by using an in situ cell death detection kit (Roche Applied Science) as described previously. 18 For the detection of reactive oxygen species (ROS), aortic tissue sections were stained with dihydroethidium (10μM, Thermo Fisher) at 37°C for 30 minutes in the dark. The presence of ROS was detected by using a fluorescence microscope (Olympus).
Statistical Analysis
Data were analyzed using SPSS software, version 22.0 (SPSS Inc). For all statistical analyses, 2-tailed probability values were used. A probability value of P less than .05 was considered significant.
Results

Increased Susceptibility to AAD Development in Mice That Received Ciprofloxacin
We examined the effect of ciprofloxacin on AAD formation in a mouse model of moderate, sporadic AAD. Sixty-seven male and 59 female C57BL/6J mice were randomly assigned into challenged (n = 86) and unchallenged groups (n = 40), aiming for an approximately 2:1 ratio. In mice that did not receive aortic challenge, ciprofloxacin alone did not induce notable aortic destruction ( Figure 1A ), aortic enlargement ( Figure 1B ), or AAD formation, although aortic dilatation was observed in 4 of 20 mice (20%) ( Figure 1C ). In challenged mice given vehicle, aortic enlargement was observed in several aortic segments ( Figure 1B ); in addition, we observed aortic dilatation in 27 of 38 mice (71%), AAD in 17 of 38 (45%), and severe AAD in 9 of 38 (24%) but no aortic rupture or death ( Figure 1C ). However, in challenged mice given ciprofloxacin, we observed severe aortic disease ( Figure 1A Figure 1D ). Our findings suggest that, rather than causing spontaneous AAD formation, ciprofloxacin significantly increases susceptibility to aortic aneurysm progression, dissection, and rupture in mice under aortic challenge.
Increased Susceptibility to AAD Development in Both Thoracic and Abdominal Aortic Segments of Mice That Received Ciprofloxacin
When we further analyzed disease formation in different aortic segments, we found that the incidences of AAD, severe AAD, and rupture were highest in the ascending aorta ( (Figure 2 ). In the ascending aorta ( Figure 2A ) and aortic arch ( Figure 2B ), the incidence of AAD was more than 3 times higher and the incidence of severe AAD was more than 10 times higher in the challenged group given ciprofloxacin than in the challenged group given vehicle. The incidence of aortic rupture was also significantly higher in the ascending aorta of mice in the challenged group given ciprofloxacin (Figure 2A ). In the descending thoracic aorta, the incidence of AAD was significantly higher in challenged mice given ciprofloxacin than in challenged mice given vehicle ( Figure 2C) . A similar pattern of AAD induction was also observed in the suprarenal abdominal aorta ( Figure 2D ) although with less fold induction than in the ascending aorta and aortic arch. Ciprofloxacin administration was not associated with a significantly increased incidence of dilatation or AAD in the infrarenal aortic region of challenged mice (data not shown). These data suggest that ciprofloxacin increases susceptibility to AAD formation in both the thoracic and abdominal aorta.
Similar Adverse Effects of Ciprofloxacin on AAD Development in Male and Female Mice
We also compared the effects of ciprofloxacin between male and female mice. In challenged mice given vehicle, the incidences of aortic dilatation (16 Figure 3) . In male and female challenged mice, the addition of ciprofloxacin markedly increased the incidence of aortic dilatation, AAD, and severe AAD ( Figure 3) . Interestingly, the fold induction of dilatation and AAD in these mice was greater in female mice than in male mice, resulting in a similar overall incidence between sexes. A similar pattern was observed in the ascending, arch, descending thoracic, and suprarenal aortic segments (data not shown).
Decreased LOX Level and Increased MMP Levels and Activity in the Aortic Wall of Challenged Mice That Received Ciprofloxacin
We further characterized histologic changes in aortic tissues of unchallenged and challenged mice given ciprofloxacin or vehicle. In aortas of unchallenged mice given ciprofloxacin, hematoxylin-eosin staining and elastic fiber staining showed a low degree of aortic destruction (eFigure 1A in the Supplement) and elastic fiber fragmentation ( Figure 4A ), respectively, but no significant destruction. In contrast, aortic challenge increased aortic destruction (eFigure 1A in the Supplement) and elastic fiber fragmentation ( Figure 4A ), which were even more pronounced in challenged mice that received ciprofloxacin.
To further investigate the potential mechanisms underlying the increased elastin destruction observed in challenged mice that received ciprofloxacin, we examined extracellular matrix (ECM) protein expression. We observed no significant difference in collagen (I and III) levels in the aortic wall between challenged mice that received ciprofloxacin and those that received vehicle (data not shown). Interestingly, the level of LOX-a protein critical for cross-linking and stabilizing elastin and collagen, as well as for ECM organization-was significantly increased in the aortic media of challenged control mice compared with that of unchallenged mice ( Figure 4B ). However, in challenged mice that received ciprofloxacin, the challenge-induced increase in LOX level was markedly diminished in the aortic media ( Figure 4B ), particularly in smooth muscle cells (SMCs) (eFigure 1B in the Supplement). Interest- ingly, LOX expression was observed in macrophages in the adventitia of the diseased aortas (eFigure 1B in the Supplement). We also examined the expression and activity of the proteins MMP-9-a key proteinase involved in ECM destructionand tissue inhibitor of metalloproteinase 1 (TIMP-1). In the aortic tissue of challenged mice that received ciprofloxacin, TIMP-1 levels were not significantly decreased, but MMP-9 protein expression ( Figure 4C ) and MMP activity (eFigure 1C in the Supplement) were significantly increased, particularly in the aortic lesion segments. These data indicate that the aortic wall of challenged mice that received ciprofloxacin had significant aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.
Increased Apoptosis and Necroptosis in the Aortic Wall of Challenged Mice That Received Ciprofloxacin
Because ciprofloxacin has been shown to suppress cell proliferation [19] [20] [21] [22] [23] [24] [25] and induce cell death, 24, 26, 27 we compared aortic cell proliferation and cell death among the groups of mice. We observed no significant difference in the detection of cell proliferation marker Ki67 between aortas of challenged mice given ciprofloxacin and those of challenged mice given vehicle (data not shown). However, the number of TUNEL-positive cells was significantly increased, particularly in lesion regions, in aortas of challenged mice given ciprofloxacin compared with challenged mice given vehicle ( Figure 5A) . Additionally, the levels of 2 key proteins in the necroptosis pathway, [28] [29] [30] [31] receptor-interacting protein kinase ( Figure 5C ), were higher in aortas from challenged mice given ciprofloxacin than in those from challenged control mice. Furthermore, the level of ROS was higher in aortic tissues of challenged mice given ciprofloxacin than in those of challenged mice given vehicle (eFigure 1D in the Supplement). These data indicate that apoptosis and necroptosis are increased in the aortic wall of challenged mice given ciprofloxacin.
Dysregulated Gene Expression in Cultured Aortic SMCs Treated with Ciprofloxacin
To understand the adverse effects of ciprofloxacin on the aortic wall, we examined the direct effects of ciprofloxacin on gene expression and on cell proliferation and cell death in cultured aortic SMCs. The treatment of SMCs with ciprofloxacin for 24 hours dose-dependently reduced the levels of several ECM proteins including LOX protein (eFigure 2A in the Supplement). Ciprofloxacin decreased LOX messenger RNA (eFigure 2B in the Supplement) levels and LOX activity (eFigure 2C in the Supplement). Ciprofloxacin also decreased TIMP-1 levels and increased levels of MMP-1 and MMP-9 but not those of MMP-2 (eFigure 2D in the Supplement). Consistent with these observations, ciprofloxacin also increased MMP activity (eFigure 2E in the Supplement). These data indicate that ciprofloxacin may reduce ECM biosynthesis and stability while promoting MMP activation and ECM destruction.
Inhibition of Cell Proliferation and Induction of Cell Injury in Cultured Aortic SMCs Treated With Ciprofloxacin
We also examined the effects of ciprofloxacin on aortic SMC proliferation and cell death. Treating aortic SMCs with ciprofloxacin (ie, 0-200 μg/mL) inhibited cell cycle progression (eFigure 3A in the Supplement), particularly at the G2 phase (eFigure 3B in the Supplement). Furthermore, ciprofloxacin induced cell death (eFigure 3C in the Supplement), which was partially due to apoptosis, as indicated by the increased number of TUNEL-stained cells (eFigure 3D in the Supplement) and the cleavage of caspase-3 (eFigure 3E in the Supplement). Ciprofloxacin also induced the phosphorylation of mixed lineage kinase domain-like (eFigure 3E in the Supplement), indicating the activation of the necroptosis pathway. Thus, consistent with previously reported findings in other cell types, 24, 26, 27 we showed that ciprofloxacin inhibits cell proliferation and induces cell death in aortic SMCs.
DNA Damage and Release of DNA to the Cytosol, Mitochondrial Dysfunction, and Activation of Cytosolic DNA Sensor Signaling Induced by Ciprofloxacin
We next investigated the mechanisms by which ciprofloxacin induces cell injury. As described in detail in eAppendix 1 in the Supplement, we found that ciprofloxacin induced the release of nuclear and mitochondrial DNA into the cytosol (eFigure 4A and B in the Supplement), mitochondrial dysfunction (eFigure 4C in the Supplement), ROS production (eFigure 4D in the Supplement), and activation of the STING (stimulator of interferon genes) cytosolic DNA sensor signaling pathway (eFigure 4E in the Supplement) in cultured aortic SMCs. We also found that silencing STING with small interfering RNA partially prevented the ciprofloxacininduced decrease in LOX and increase in MMP-1 and MMP-9 protein expression (eFigure 4F in the Supplement). Together, these data suggest that ciprofloxacin causes mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Furthermore, these data indicate that the ciprofloxacin-induced disruption of ECM integrity may be mediated by the activation of the cytosolic DNA sensor STING.
Discussion
In this study, we showed that ciprofloxacin significantly increased the incidence of aortic dissection and rupture in a mouse model of moderate, sporadic AAD. These effects of ciprofloxacin were observed in both thoracic and abdominal aortic segments and were similar in male and female mice. Compared with aortic tissues from challenged control mice, those from challenged mice given ciprofloxacin showed decreased LOX expression and activity, increased MMP levels and activity, and increased elastic fiber fragmentation and cell injury. Although ciprofloxacin alone caused mild aortic elastic fiber breakage, it did not induce spontaneous AAD in the absence of exogenous stress. Our results suggest that ciprofloxacin use may increase susceptibility to AAD formation and lethal rupture. Wild-type mice were either unchallenged or challenged with a high-fat diet for 8 weeks and infused with angiotensin II during the last 4 weeks. Unchallenged and challenged mice were given vehicle or ciprofloxacin during the last 4 weeks.
Comparison of the overall incidences of aortic dilatation, AAD (aneurysm, dissection, and rupture), severe AAD (dissection and rupture), and rupture in all aortic segments showing that ciprofloxacin treatment enhanced challenged-induced AAD formation and severity similarly in male and female mice. Recently, authors of 2 independent observational clinical studies have suggested that fluoroquinolone use may be associated with an increased risk of AAD (eAppendix 2 in the Supplement). 14, 15 Although the causal effect cannot be determined by the results of these observational studies, this alarming association raises the concern that taking fluoroquinolones may promote AAD formation or increase the risk of disease progression and rupture in patients with AAD. We showed that although ciprofloxacin alone did not induce spontaneous AAD in the absence of exogenous stress, it significantly increased the incidence and severity of challenge-induced AAD, particularly with respect to dissection and rupture. Given that fluoroquinolones are widely used in the general population for a variety of common infections [2] [3] [4] (and ironically in patients with infected AAD Here, we showed that ciprofloxacin induced DNA doublestrand breaks in the nucleus (as indicated by TUNEL analysis) and the release of nuclear and mitochondrial DNA into the cytosol of aortic SMCs. As a result of mitochondrial DNA damage, 80,84-88 ciprofloxacin-treated cells exhibited significant mitochondrial dysfunction and increased intracellular ROS production. Our findings suggest that, as a topoisomerase inhibitor, ciprofloxacin causes mitochondrial DNA and nuclear DNA damage and may lead to mitochondrial dysfunction, ROS production, cell dysfunction, and death. Finally, we observed that activation of STING, 89-93 a proinflammatory cytosolic DNA sensor involved in cell dysfunction and tissue destruction, 94,95 is involved in the ciprofloxacin-induced suppression of LOX expression and induction of MMP expression. Together, our findings point to a novel mechanism underlying the toxic cellular effects of ciprofloxacin.
Limitations
We acknowledge that our study has limitations. We did not test the effects of other fluoroquinolones. However, considering that fluoroquinolones exert their antibiotic effects through the same mechanism, we expect that different fluoroquinolones may have similar effects on the aortic wall. Additionally, we did not perform experiments to determine the time-and dose-dependent effects of ciprofloxacin in our model. Further studies are warranted to address these matters. The addition of periodic aortic ultrasound to evaluate rates of aortic dilatation would be useful in this context.
Conclusions
Although ciprofloxacin alone does not induce spontaneous AAD, it significantly increases susceptibility to challenge-induced 
eMethods. Supplemental methods
Animal Studies
We evaluated the effects of ciprofloxacin on aortic aneurysm and dissection (AAD) development in a mouse model of moderate, sporadic AAD. Four-week-old wild-type (C57BL/6J) male and female mice were randomly assigned to the challenged or unchallenged group, aiming for an approximately 2:1 ratio. In the challenged group, mice were fed with a high-fat diet (HFD) containing 20% protein, 40% carbohydrate, 40% fat, and 1.25% cholesterol (Research Diets, Inc., D12108C, New Brunswick, NJ) for 8 weeks and were subcutaneously infused with 1000 ng/min/kg angiotensin II (AngII; Sigma-Aldrich Corp., St. Louis, MO) through an osmotic minipump (Model 2004; ALZA Scientific Products, Mountain View, CA) during the last 4 weeks. In the unchallenged control group, mice were fed a normal chow diet for 8 weeks and were infused with saline during the last 4 weeks. The challenged and unchallenged groups were further randomized and received either ciprofloxacin (100 mg/kg/day, 5% HCl in saline) or vehicle (5% HCl in saline) through daily gavage during the AngII or saline infusion period. At the end of the 8-week study period, mice were euthanized with CO 2 inhalation. The aorta of each mouse was exposed and rinsed with cold phosphate-buffered saline (PBS). The peri-aortic tissues were removed. The aorta was excised and further cleaned and rinsed with cold PBS to remove any residual blood in the lumen. The aorta was then processed for AAD evaluation and tissue analysis. Different aortic segments were fixed in optimal cutting temperature (OCT) compound (Tissue-Tek; Miles Inc., Elkhart, Illinois) for immunofluorescence staining or were snap-frozen for protein analysis.
We chose the dose of ciprofloxacin based on the standard lower dose used to treat patients with common indications (500 mg/day, approximately 8.3 mg/kg/day) and used the standard conversion factor (12.3) for calculating an equivalent dose for mice. 1 We determined the sample size of mice based on preliminary data that indicated the overall incidence of AAD in all aortic segments was 40% for challenged mice that received vehicle and 85% for challenged mice that received ciprofloxacin. To show that the difference in the incidence of AAD between these groups was statistically significant (at =0.05 with 80% power), we included 18 to 20 mice in each challenged group.
Measurement of Aortic Diameter
For each extracted aorta, we evaluated the ascending, arch, descending thoracic, suprarenal abdominal, and infrarenal aortic segments. Images of the aorta were obtained by using an Olympus SZX7 microscope at a magnification of 0.4X (scale bar=2 mm), and the diameter of each aortic segment was measured with DP2-BSW software (Olympus Corporation, Houston, TX). The median diameters of different aortic segments were compared between groups.
Evaluation of Aortic Aneurysm, Dissection, and Rupture
For each aortic segment, aortic dilatation was defined as an aortic diameter ≥1.25 times but <1.5 times the mean aortic diameter of the segment in unchallenged mice treated with vehicle. Aortic aneurysm was defined as an aortic diameter ≥1.5 times the mean aortic diameter of the segment in unchallenged mice treated with vehicle. Aortic dissection was defined as the presence of hematoma within the aortic wall detected on gross examination, or as the presence of layer separation within the aortic media or medial-adventitial boundary (with a false lumen hematoma) detected on aortic histology. Aortic rupture and premature death were documented.
Classification of AAD Severity
The severity of AAD was classified as one of the following by using our previously reported 2 modification of the classification system described by Daugherty and colleagues 3 : normal aorta; dilated aorta; aortic aneurysm without dissection; aortic dissection (as indicated by intramural thrombus) without aneurysm; aortic aneurysm with dissection; or ruptured aorta. We defined the category AAD as the presence of aneurysm, dissection, or rupture. Severe AAD was defined as the presence of dissection or rupture. Aneurysmal tissue was evaluated by 4 independent observers who were blinded to the experimental groups. In the case of a discrepancy, the observers discussed the case and agreed on the classification.
Elastic Fiber Staining
Aortic sections were stained with Verhoeff-Van Gieson elastin staining by using the Elastic Stain Kit (Sigma-Aldrich) according to the manufacturer's instructions. Aortic sections were examined by 2 independent observers who were blinded to the experimental groups. Elastic fiber fragmentation was scored (Grade 0 = none; Grade 1 = minimal; Grade 2 = moderate; Grade 3 = severe).
Immunofluorescence Staining
OCT-embedded aortic sections and treated cells were fixed with Cytofix (BD Biosciences, San Jose, CA) on slides and permeabilized with Perm/Wash (BD Biosciences). Nonspecific staining was reduced by blocking with 5% normal blocking serum. The sections or cells were then incubated with primary antibody at room temperature for 2 hours or at 4°C overnight, washed with PBS, and incubated with secondary antibody conjugated to an Alexa Fluor dye such as Alexa Fluor-488, -555, or -647 (ThermoFisher Scientific, Waltham, MA). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Slides incubated with secondary antibody alone were used as negative controls. Primary and secondary antibodies used for immunofluorescence staining are listed in eTable.
Tissue sections were examined by using a Leica microscope (Leica Microsystems Inc., Buffalo Grove, IL) and by using a Leica SP5 confocal microscope (Leica). For quantification, images were captured from 3 to 4 randomly selected visual fields (excluding the thrombosed false lumen) per aortic section (magnification, 200X). The positive-staining area and the evaluated aortic area were measured by using Image-Pro Plus V7.0 software (Media Cybernetics, Inc., Bethesda, MD), and the positive-staining area was normalized to the evaluated aortic area. The same exposure time was used for all samples. Aortic tissues from 5 mice in each group were analyzed. The mean or median positive percentages were calculated and compared between groups.
MMP Activity Determined by Using In Situ Zymography
MMP activity in the aortic wall was determined by using gelatin conjugated with quenched fluorescein (DQ gelatin; Invitrogen Corporation, Carlsbad, CA) as a substrate, according to the manufacturer's instructions. Briefly, frozen aortic sections were incubated with 0.1 mg/mL DQ gelatin in 1% low-melting agarose at 37°C for 48 hours. Fluorescence was examined by using fluorescence microscopy. Zymographic images were acquired by using identical setting and exposure times.
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay
Frozen sections of aorta or treated SMCs were fixed with 4% paraformaldehyde in PBS for 10 minutes and permeabilized with 0.2% Triton X-100 for 5 minutes. The fixed tissues or cells were incubated for 1 hour at 37°C with TUNEL reaction mixture containing terminal deoxynucleotidyl transferase. After TUNEL staining, nuclei were counterstained with DAPI (0.1 g/mL). Terminal deoxynucleotidyl transferase-free labeling mixture was used in negative control reactions. For each aortic section or cell treatment condition, we captured images from 5 randomly selected views. For each image, the number of positive cells and the number of total nuclei were quantified, and the percentage of positive cells was calculated.
as a green monomer outside depolarized dysfunctional mitochondria. Cells were incubated with 20 µM JC-1 at 37°C for 20 minutes and washed twice with PBS. Cells were observed with a Leica SP5 confocal microscope (Leica). The red and green fluorescence signals were measured, and the red/green fluorescence ratio was calculated and compared among groups.
Statistical Analysis
Data were analyzed by using SPSS software, version 22.0 (SPSS Inc., Chicago, IL). Categorical variables were compared between groups by using the chi squared test. All quantitative data are presented as the mean ± standard deviation. Normality of the data was examined by using the Kolmogorov-Smirnov test. For variables without violation of the normality assumption, two-group comparisons were performed by using the t test. Multi-group comparisons were performed by using one-way analysis of variance for data with unequal variances. For variables with violation of the normality assumption, two-group comparisons were performed by using the Mann-Whitney test, and multi-group comparisons were performed by using the Kruskal-Wallis test. Kaplan-Meier survival curves were plotted to analyze survival rates in mice; curves were compared by using the log-rank test. For all statistical analyses, twotailed probability values were used. A probability value (P) of P<0.05 was considered significant. eFigure 4. Increased DNA damage and its release into the cytosol and the activation of cytosolic DNA sensor signaling in aortic SMCs treated with ciprofloxacin A-D, Aortic SMCs were treated with the indicated dose of ciprofloxacin for 24 hours (n=3-4 biologic replicates). A, Costaining of double-stranded DNA (dsDNA) with anti-dsDNA antibody and mitochondria with MitoTracker showing the detection of nuclear DNA (dsDNA in the nucleus), mitochondrial DNA (mtDNA, dsDNA that colocalized with MitoTracker), and cytosolic DNA (dsDNA that did not colocalize with either mitochondria or the nucleus). Ciprofloxacin triggered the release of dsDNA into the cytosol. B, Cytosolic nuclear DNA and mitochondrial DNA were measured by performing PCR analysis of DNA in the cytosolic fraction by using nuclear or mitochondrial DNA sequences as primer sequences. Ciprofloxacin increased the ratio of mtDNA/nuclear DNA (n=3 biologic replicates). C, JC-1 staining showing that ciprofloxacin decreased the number of red aggregates and increased the number of green monomers (thus decreasing the red/green fluorescence ratio), indicating reduced mitochondrial membrane potential ( m ) and mitochondrial dysfunction. D, Representative dihydroethidium (DHE) staining showing that ciprofloxacin treatment increased reactive oxygen species (ROS) production. E, Representative western blot analysis showing that ciprofloxacin increased the expression of STING and the phosphorylation of IRF3 in aortic SMCs (n=3 biologic replicates). F, Representative western blot analysis showing the effect of silencing STING on the ciprofloxacin-induced dysregulation of LOX and MMP expression. Aortic SMCs were transfected with scramble siRNA or STING siRNA and then treated with or without 100 µg/ml of ciprofloxacin for 24 hours (n=3-5 biologic replicates). Silencing the expression of STING prevented ciprofloxacin-induced dysregulation of LOX and MMP expression. eAppendix 1. DNA damage and release to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling by ciprofloxacin
We next investigated the mechanisms by which ciprofloxacin dysregulates aortic SMC gene expression and induces cell injury. Quinolones such as ciprofloxacin are known to target DNA topoisomerases, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] which are enzymes that generate a transient DNA double-strand break, untangle duplex DNA, and release torsional DNA stress to allow for DNA replication. 14, 15 Because stabilized DNA-topoisomerase complexes induced by ciprofloxacin can generate DNA double-strand breaks, [16] [17] [18] we examined whether ciprofloxacin causes DNA damage and the release of DNA into the cytosol in aortic SMCs. By costaining dsDNA and mitochondria (MitoTracker), we detected cytosolic DNA-dsDNA that did not colocalize with either mitochondria or nuclei (eFigure 4A). We found that cytosolic DNA was barely detectable in untreated SMCs but was markedly increased in SMCs treated with ciprofloxacin. Furthermore, when we performed PCR analysis of cytosolic DNA by using mitochondrial DNA or nuclear DNA sequences as primers, we found that ciprofloxacin significantly increased the amount of nuclear DNA (data not shown) and mitochondrial DNA in the cytosolic fraction, as well as the ratio of mitochondrial DNA/nuclear DNA (eFigure 4B). These data suggest that ciprofloxacin causes nuclear and mitochondrial DNA damage and the release of DNA into the cytosol.
Because DNA topoisomerases are also present in mitochondria, ciprofloxacin may target mitochondrial DNA topoisomerases and cause mitochondrial DNA damage, which is known to cause DNA depletion and mitochondrial dysfunction. 13, [19] [20] [21] [22] [23] We therefore examined the effects of ciprofloxacin on mitochondrial function by measuring mitochondrial membrane potential ( m ) in aortic SMCs by using JC-1 staining. JC-1 is a cationic fluorescent dye that forms red aggregates in polarized functional mitochondria while remaining as a green monomer outside depolarized mitochondria. In aortic SMCs, ciprofloxacin treatment decreased the number of red aggregates and increased the number of green monomers, resulting in a decreased red/green fluorescence ratio (eFigure 4C) that indicated a reduced m and mitochondrial dysfunction. Consistent with this finding, we observed a significant increase in intracellular ROS in ciprofloxacin-treated aortic SMCs (eFigure 4D).
Finally, we examined the mechanism underlying DNA damage-induced ECM gene dysregulation in ciprofloxacin-treated aortic SMCs. Recent studies have suggested that the STING (stimulator of interferon genes) pathway is an important signaling pathway that detects cytosolic DNA and triggers the inflammatory response. [24] [25] [26] [27] [28] Therefore, we investigated whether this mechanism is activated by ciprofloxacin treatment and mediates ciprofloxacin-induced ECM gene dysregulation in aortic SMCs. We found that ciprofloxacin treatment increased the expression of STING and the phosphorylation of IRF3 (eFigure 4E), indicating the activation of this pathway. Importantly, silencing STING with siRNA partially prevented the ciprofloxacininduced decrease in LOX and increase in MMP-1 and MMP-9 protein expression (eFigure 4F), suggesting that STING is involved in the ciprofloxacin-induced suppression of LOX expression and the induction of MMP expression. Together, these data suggest that ciprofloxacin treatment promotes the release of nuclear and mitochondrial DNA into the cytosol and the activation of the cytosolic DNA sensor STING, which may mediate the effect of ciprofloxacin on the disruption of ECM integrity. eAppendix 2. Two independent observational clinical studies suggesting that fluoroquinolone use may be associated with an increased risk of aortic aneurysm and dissection In a case-control analysis of 1477 patients and 147,700 matched controls in Taiwan, Lee and colleagues 29 found that fluoroquinolone use was associated with an increased risk of aortic aneurysm or dissection (rate ratio, 2.43; 95% confidence interval [CI], 1.83-3.22). In a population-based longitudinal cohort study of 1,744,360 individuals ≥ 65 years of age in Ontario, Canada, Daneman and colleagues 30 found that aortic aneurysms were more common in patients treated with fluoroquinolones, especially in those who were currently receiving treatment (hazard ratio [HR], 2.24; 95% CI, 2.02-2.49).
